Ann: Q2 2024 Investor Webinar Presentation, page-14

Agreed, sell lesser indication and keep in-house with the kidney.

I was looking forward to this event and was not disappointed. Very positive progress presentation filling many gaps.

I was impressed with the time taken to answer questions. The time was NOT rushed, and appeared as though all questions asked were addressed. Watch the video replay above, I think it is well worth the time. Extremely informative, well done.

Two questions that should have been asked, my fault,
what would our value be relative to peers in USA,
please elaborate on potential commercialization during phase 3 study as disclosed previously.